Clinical trials: Hepatitis C Virus (HCV)
Drug Use, HCV Infection
A Community-based Intervention Among Active Drug Users in Montpellier
The study aims to assess the effectiveness of a community-based model of HCV mass screening associated with an immediate HCV treatment on the cascade of care among active drug users (DUs) in the city of Montpellier, France.
- Trial name
- ICONE (NCT04008927)
- Testing
- HCV screening, Diagnosis of hepatitis C, HCV treatment
- Where
- France
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Genotype 1 Chronic Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects.
- Trial name
- NCT00606086
- Testing
- GI-5005, Pegylated Interferon and Ribavirin
- Where
- 25 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlobeImmune
Hepatitis C Virus
High Dose Insulin Therapy to Improve Liver Function
Insulin resistance is one of the key factors in defining a progressive course of chronic Hepatitis C virus (HCV) infection and hepatic fibrosis.
- Trial name
- NCT01271140
- Testing
- Insulin
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatitis C, Hepatitis B
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.
- Conditions
- Hepatitis C, Hepatitis B, Liver Cirrhoses
- Trial name
- NCT03620474
- Testing
- PRI-724
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Kiminori Kimura, MD
Hepatitis C
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
- Trial name
- NCT02515279
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- Austria
- Volunteers
- 463 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir
To evaluate the early detection of HCC in patients Taking Sofosbuvir and Daclatasvir.
- Trial name
- NCT03247296
- Testing
- Sofosbuvir 400 mg, Daclatasvir, Ribavirin
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- MTI University
Hepatitis C, Chronic
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection…
- Trial name
- NCT04943588
- Testing
- HCV RNA (PCR), HCV Antibody test (Point of care), AST/ALT and platelets measurement
- Where
- Pakistan
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
HCV Infection
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected subjects.
- Trial name
- NCT01181427
- Testing
- ABT-267, Blood Sample Collection, Cytochrome P450 inhibitor
- Where
- 3 sites in United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Abbott
Chronic Hepatitis C
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection
This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
- Trial name
- NCT02253550
- Testing
- Simeprevir, Sofosbuvir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter J. Ruane, M.D.
Hepatitis B, Hepatitis C
Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants
The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States (US) is relatively low. However, immigrant populations in the US from Asia and sub-Saharan Africa have substantially higher prevalence…
- Conditions
- Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- NCT02366286
- Where
- United States
- Volunteers
- 892 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hepatitis C
Hepatitis C Screening in the Primary Care Setting
The purpose of this study is to determine whether patient education improves Hepatitis C screening in the primary care setting.
- Trial name
- NCT03316313
- Testing
- Hepatitis C Antibody
- Volunteers
- 503 people
- Sponsor
- New York Institute of Technology
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Cirrhosis, Cirrhosis Due to Hepatitis B
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
- Conditions
- Cirrhosis, Cirrhosis Due to Hepatitis B, Cirrhosis and Chronic Liver Disease, Cirrhosis Due to Hepatitis C
- Trial name
- AMULET (NCT06658782)
- Testing
- non contrast enhanced MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
Chronic Hepatitis C
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
This study is a two-way, non-interventional long-term dynamic follow-up clinical observational cohort study. In the Second Division of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, chronic hepatitis C…
- Trial name
- NCT04301882
- Testing
- interferon combined with ribavirin (PR) antiviral therapy, direct antiviral drugs (DAAs)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
- Trial name
- NCT02446717
- Testing
- ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530
- Volunteers
- 141 people
- Sponsor
- AbbVie
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02476617
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 25 people
- Sponsor
- AbbVie
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00040027
- Testing
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Hepatitis C
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir…
- Trial name
- NCT02441283
- Testing
- ABT-493, ABT-530
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 384 people
- Sponsor
- AbbVie
Drug Abuse, Intravenous
Case Management in HCV Infected PWID
To study the impact of case management on the outcome of the care of chronic hepatitis C in people who inject drugs (PWID). By creating the function of case manager, the investigators will target all the barriers to care of the…
- Trial name
- CM-HCV (NCT03106194)
- Testing
- case management
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Hasselt University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.